The goal of this study was to explore healthcare providers’ experiences with specialty medications distributed via Limited Distribution Networks (LDN) that do not include IHSSPs. Participants reported barriers to navigating LDNs that can interfere with clinic workflow and patient care. IHSSPs may reduce clinic burden by helping patients access, afford, and remain on therapy.

This two-part study aimed to identify the rates and reasons of PMN for specialty oral oncolytic agents. In Part I, we used 24 methods to calculate PMN based on combinations of three parameters. In Part II, we reviewed electronic medical records of 198 prescriptions considered PMN by our previous calculation.

This study demonstrated high medication adherence rates and low patient out-of-pocket costs for patients in an integrated clinic and specialty pharmacy. Adherence measured using mean proportion of days covered was 0.89 and 80% of patients were adherent (PDC≥0.80). Rates of financial assistance were high and low out-of-pocket costs were associated with higher adherence.

This retrospective cohort analysis of adult patients with PAH prescribed PDE-5I therapy through an integrated model fournd that patients achieved high adherence rates despite almost half reporting side effects and a quarter reporting hospitalization. Median out-of-pocket costs were $14, indicating the important role specialty pharmacists play in ensuring affordable therapy.

In this study, we explored factors related to teriparatide completion. We found that patients utilizing VSP services were 62% more likely to complete teriparatide and 49% less likely to drop out of treatment after completing 12 months of teriparatide compared to non-VSP patients. Additionally, most patients (64%) required the use a financial assistance program only available to VSP patients. Smoking status also significantly impacted teriparatide completion.

In this study, we examined patients with osteoporosis prescribed denosumab. We explored the association between treatment lapses and discontinuations with fracture incidence. We also assessed reasons patients incurred a lapse in therapy or discontinued treatment, and discussed the role of the specialty pharmacist in supporting patient adherence and persistence.

The objective of this study was to measure time to medication access for prescription CBD from patient referral to first shipment when insurance approval process is managed by embedded specialty pharmacy team.Median time from initial assessment to first shipment was 7 days (IQR 4-13). Of patients for whom the CPhT helped obtain financial assistance (n = 14, 10%), all had $0 costs after assistance.

In this study, we found the time to access pimavanserin reduced by 21 days on average after pharmacist integration. Similarly, the rate of third party approval increased by 16% and treatment initiation increased by 18%.

Vanderbilt Specialty Pharmacy (VSP) embeds pharmacists within an outpatient MS clinic to provide medication management and address barriers to adherence. We found an average adherence rate of 94% as measured by proportion of days covered (PDC), with 89% of all VSP patients achieving the industry standard of 80% PDC. Additionally, results indicate that ensuring financial assistance and low out-of-pocket costs are associated with high adherence to DMT within an integrated specialty clinic.

This study evaluated medication access rates in patients prescribed a PCSK9 inhibitor at a healthcare system with integrated specialty pharmacy services. Overall, 96% of prescriptions resulted in access to a PCSK9 inhibitor, with a median time to approval of 8 days. This high level of access supports this model as a best practice for prescribing PCSK9 inhibitor therapy.